The marker "Anti-Streptococcal A (IgG)" is a specialized test designed to detect the presence of IgG antibodies against Streptococcus A bacteria in the blood. Streptococcus A is a type of bacteria that can cause various infections, ranging from mild throat infections (like strep throat) to more severe diseases such as rheumatic fever, which can affect the heart, joints, skin, and brain. The presence of IgG antibodies specifically indicates a past or ongoing immune response to this bacterium, suggesting previous exposure or infection.

Anti-Tau (IgG + IgA) measures the immune system’s response to tau protein, a structural protein in neurons that helps stabilize microtubules—the internal “tracks” used for nutrient delivery, cell stability, and healthy nerve communication. When tau proteins become damaged or misfolded, they can form tau tangles, which are associated with: • Neuroinflammation • Neuronal instability and injury • Impaired cellular transport and energy function • Cognitive decline in neurodegenerative conditions This test does not diagnose Alzheimer's disease, frontotemporal dementia, or other tau-related disorders. Rather, it helps identify whether the immune system is reacting to tau proteins, which can signal neuroimmune activation, neuronal stress, or early protective immune surveillance. A mild elevation in Anti-Tau (IgG + IgA) suggests early immune awareness of tau proteins, which may reflect subtle neuroinflammation or neuronal stress. This does not diagnose Alzheimer's or other neurodegenerative diseases. What it may suggest • Early-phase immune signaling around neuronal proteins • Mild oxidative or metabolic stress affecting the brain • Possible blood-brain barrier or tau turnover shifts Supportive steps • Prioritize sleep and stress regulation • Anti-inflammatory, polyphenol-rich diet • Regular aerobic + strength exercise • Maintain blood sugar balance • Support gut-brain health Monitoring and preventive care are reasonable, especially if symptoms or strong family history are present.

Part of AVISE CTD, Exagen

Associated Disease: Hashimoto’s Thyroiditis & Graves’ Disease Sensitivity: 60-85% Interpretation: Anti-thyroglobulin antibodies are found in 60-85% of patients with Hashimoto’s thyroiditis and 30-80% of patients with Graves’ disease.

Anti-Tissue Transglutaminase IgA (tTG IgA): What Does It Mean? The Anti-Tissue Transglutaminase IgA (tTG IgA) marker is the gold standard test for screening celiac disease, an autoimmune condition triggered by gluten consumption. This test measures IgA antibodies produced by the immune system when it mistakenly targets tissue transglutaminase (tTG), an enzyme found in the lining of the small intestine. Elevated tTG IgA levels are a strong indicator of celiac disease, as the immune reaction causes inflammation and damage to the intestinal lining, leading to malabsorption of nutrients. Why Is tTG IgA Important? The tTG IgA test is highly sensitive and specific for detecting celiac disease, making it the preferred initial screening tool. When gluten is consumed, individuals with celiac disease produce high levels of tTG IgA as part of their immune response. What Do Elevated tTG IgA Levels Mean? Celiac Disease: Elevated tTG IgA strongly suggests celiac disease, especially when combined with symptoms like digestive issues, fatigue, or nutrient deficiencies. Gluten Exposure: If already on a gluten-free diet, elevated tTG IgA may indicate accidental gluten exposure. False Negatives: If you have IgA deficiency (common in about 1 in 500 people), tTG IgA levels may appear normal even if celiac disease is present. In this case, tTG IgG or other markers like DGP IgG should be tested. Next Steps If your tTG IgA levels are elevated, your healthcare provider may recommend further testing, such as an intestinal biopsy to confirm celiac disease or genetic testing (HLA-DQ2/DQ8) to evaluate genetic predisposition. If diagnosed, a gluten-free diet is the primary treatment to reduce symptoms and heal the intestine. Key Takeaway The tTG IgA marker is the most reliable and widely used test for diagnosing celiac disease. Elevated levels indicate a strong likelihood of gluten-induced intestinal damage. If your tTG IgA is elevated, consult your healthcare provider for further testing and guidance on managing gluten-related symptoms.

Anti-Tissue Transglutaminase IgG (tTG IgG): What Does It Mean? The Anti-Tissue Transglutaminase IgG (tTG IgG) marker is a key component of celiac disease testing. It measures antibodies produced by the immune system in response to tissue transglutaminase (tTG), an enzyme found in the lining of the small intestine. When individuals with celiac disease consume gluten—a protein in wheat, barley, and rye—their immune system mistakenly targets tTG, leading to the production of tTG antibodies, inflammation, and damage to the intestinal lining. Why Is tTG IgG Important? While the IgA version of tTG (tTG IgA) is the primary marker for celiac disease, tTG IgG is crucial for individuals with IgA deficiency, a condition where the body produces insufficient Immunoglobulin A. Since IgA deficiency occurs in about 1 in 500 people, testing tTG IgG ensures accurate results even when tTG IgA is unreliable. Elevated tTG IgG levels may suggest celiac disease or an immune reaction to gluten. What Do Elevated tTG IgG Levels Mean? If your tTG IgG levels are elevated, it may indicate: Celiac Disease: Your immune system is reacting to gluten, causing damage to the intestines. Non-Celiac Gluten Sensitivity: In some cases, elevated IgG antibodies may occur without full-blown celiac disease. False Positives: Elevated tTG IgG can occasionally result from other conditions, such as liver disease, infections, or autoimmune disorders. Next Steps An elevated tTG IgG result should be interpreted alongside other markers (like deamidated gliadin peptide IgG) and clinical findings. Your healthcare provider may recommend further testing, such as an intestinal biopsy or a gluten-free diet trial, to confirm celiac disease. Key Takeaway The tTG IgG marker is vital for detecting gluten-related disorders, particularly in individuals with IgA deficiency. If elevated, it points to a potential immune response to gluten and warrants further evaluation to understand its cause and ensure proper management.

The Anti-Titin (IgG + IgA) biomarker, measured in Vibrant Wellness' Neural Zoomer Plus panel, assesses immune reactivity to titin, a giant protein critical for muscle elasticity and contraction. This test helps identify autoimmune responses targeting neuromuscular tissues, which may underlie conditions like myasthenia gravis and thymoma-associated syndromes. What It Measures The test detects IgG and IgA antibodies against titin, a structural protein in skeletal and cardiac muscle. Titin stabilizes sarcomeres during muscle contraction, and autoantibodies against it are often linked to neuromuscular junction dysfunction. Clinical Relevance Anti-Titin antibodies are associated with: Myasthenia Gravis (MG): Found in approximately 30% of generalized MG cases, particularly in patients with thymoma (a tumor of the thymus). Associated with severe disease phenotypes and poorer response to acetylcholinesterase inhibitors. Thymoma Screening: The presence of Anti-Titin antibodies may prompt imaging (e.g., chest CT) to rule out thymic tumors. Late-Onset MG: More common in patients over 50, often without thymoma, but with higher rates of muscle-specific kinase (MuSK) antibodies. Interpretation of Results Positive Result (High/Moderate Reactivity): Suggests autoimmune targeting of muscle proteins. Correlates with myasthenia gravis, thymoma, or other neuromuscular disorders. Requires clinical confirmation (e.g., electromyography, acetylcholine receptor antibody testing). Negative Result: Reduces likelihood of titin-associated autoimmune myasthenia but does not exclude other neuromuscular conditions. Testing Considerations Panel Context: The Neural Zoomer Plus evaluates 48 neurological antigens, including titin, to map autoimmune contributors to symptoms like muscle weakness or fatigue. Complementary Tests: Anti-Acetylcholine Receptor Antibodies: Confirms MG diagnosis. Chest Imaging: For thymoma detection. Limitations: Low titin antibody titers may occur in non-autoimmune conditions (e.g., aging, cardiac disease). Results should be interpreted alongside symptoms and other biomarkers. Conclusion Anti-Titin (IgG + IgA) testing on the Neural Zoomer Plus aids in diagnosing autoimmune neuromuscular disorders, particularly myasthenia gravis with thymoma. While positive results guide targeted interventions (e.g., immunosuppression, thymectomy), clinical correlation remains essential.

Anti-TPO antibodies (Anti-Thyroid Peroxidase antibodies) are autoantibodies directed against thyroid peroxidase, an enzyme crucial for the production of thyroid hormones. These antibodies are a key marker in autoimmune thyroid diseases, particularly Hashimoto's thyroiditis and, to a lesser extent, Graves' disease. In Hashimoto's thyroiditis, which is the most common cause of hypothyroidism, the presence of Anti-TPO antibodies signifies an immune system attack on the thyroid gland, leading to inflammation, damage, and eventually reduced thyroid function. Patients with elevated levels of Anti-TPO antibodies are at an increased risk of developing hypothyroidism, even if their thyroid function is normal at the time of testing. In Graves' disease, which is characterized by hyperthyroidism, Anti-TPO antibodies are less commonly present but can coexist with other types of thyroid autoantibodies. The "RDL" here likely refers to the specific laboratory or testing methodology for detecting these antibodies, typically done through immunoassay techniques like ELISA. Testing for Anti-TPO antibodies is an essential component of diagnosing and managing autoimmune thyroid disorders. It helps in distinguishing autoimmune thyroiditis from other forms of thyroid dysfunction. Beyond thyroid diseases, elevated Anti-TPO antibody levels can also be found in other autoimmune conditions and in a proportion of the general population, especially among older women, where their presence might not always indicate active thyroid disease. The presence of these antibodies, particularly in high titers, often necessitates regular monitoring of thyroid function and can guide the management and treatment of patients with or at risk of thyroid diseases.